Clinuvel Pharmaceuticals Ltd
OTC:CLVLY

Watchlist Manager
Clinuvel Pharmaceuticals Ltd Logo
Clinuvel Pharmaceuticals Ltd
OTC:CLVLY
Watchlist
Price: 6.75 USD -0.74% Market Closed
Market Cap: 348.2m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

CLVLY Price Targets Summary
Clinuvel Pharmaceuticals Ltd

Wall Street analysts forecast CLVLY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CLVLY is 17.44 USD with a low forecast of 9.98 USD and a high forecast of 27.29 USD.

CLVLY Lowest Forecast
Wall Street Target
9.98 USD
48% Upside
CLVLY Average Forecast
Wall Street Target
17.44 USD
158% Upside
CLVLY Highest Forecast
Wall Street Target
27.29 USD
304% Upside
Lowest
Price Target
9.98 USD
48% Upside
Average
Price Target
17.44 USD
158% Upside
Highest
Price Target
27.29 USD
304% Upside
Clinuvel Pharmaceuticals Ltd Competitors:
Price Targets
ELUT
Elutia Inc
273% Upside
XGN
Exagen Inc
12% Upside
NTLA
Intellia Therapeutics Inc
234% Upside
PAR
Paradigm Biopharmaceuticals Ltd
83% Upside
ELUT
Elutia Inc
273% Upside
XGN
Exagen Inc
12% Upside
NTLA
Intellia Therapeutics Inc
234% Upside
PAR
Paradigm Biopharmaceuticals Ltd
83% Upside
ALDX
Aldeyra Therapeutics Inc
76% Upside
KNSA
Kiniksa Pharmaceuticals Ltd
28% Upside
PBYI
Puma Biotechnology Inc
28% Upside

Revenue
Forecast

Revenue Estimate
Clinuvel Pharmaceuticals Ltd

For the last 8 years the compound annual growth rate for Clinuvel Pharmaceuticals Ltd's revenue is 39%. The projected CAGR for the next 4 years is 6%.

39%
Past Growth
6%
Estimated Growth
Estimates Accuracy
3%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Clinuvel Pharmaceuticals Ltd

The compound annual growth rate of Clinuvel Pharmaceuticals Ltd's operating income for the next 4 years is 0%.

N/A
Past Growth
0%
Estimated Growth
Estimates Accuracy
22%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Clinuvel Pharmaceuticals Ltd

The compound annual growth rate of Clinuvel Pharmaceuticals Ltd's net income for the next 4 years is 6%.

N/A
Past Growth
6%
Estimated Growth
Estimates Accuracy
3%
Average Beat
What are analyst estimates?

See Also

Summary
CLVLY intrinsic value, competitors valuation, and company profile.
DCF Valuation
CLVLY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CLVLY stock valuation using valuation multiples.
Wall Street Estimates
CLVLY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CLVLY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CLVLY's stock price target?
Price Target
17.44 USD

According to Wall Street analysts, the average 1-year price target for CLVLY is 17.44 USD with a low forecast of 9.98 USD and a high forecast of 27.29 USD.

What is Clinuvel Pharmaceuticals Ltd's Revenue forecast?
Projected CAGR
6%

For the last 8 years the compound annual growth rate for Clinuvel Pharmaceuticals Ltd's revenue is 39%. The projected CAGR for the next 4 years is 6%.

What is Clinuvel Pharmaceuticals Ltd's Operating Income forecast?
Projected CAGR
0%

The compound annual growth rate of Clinuvel Pharmaceuticals Ltd's operating income for the next 4 years is 0%.

What is Clinuvel Pharmaceuticals Ltd's Net Income forecast?
Projected CAGR
6%

The compound annual growth rate of Clinuvel Pharmaceuticals Ltd's net income for the next 4 years is 6%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 267,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.